Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $2.76 billion. The enterprise value is $3.62 billion.
| Market Cap | 2.76B |
| Enterprise Value | 3.62B |
Important Dates
The last earnings date was Thursday, February 5, 2026, before market open.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 46.47 million shares outstanding. The number of shares has decreased by -6.04% in one year.
| Current Share Class | 46.47M |
| Shares Outstanding | 46.47M |
| Shares Change (YoY) | -6.04% |
| Shares Change (QoQ) | -1.42% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 105.73% |
| Float | 45.88M |
Valuation Ratios
The trailing PE ratio is 16.28 and the forward PE ratio is 11.51. Haemonetics's PEG ratio is 1.05.
| PE Ratio | 16.28 |
| Forward PE | 11.51 |
| PS Ratio | 2.16 |
| Forward PS | 1.99 |
| PB Ratio | 3.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.97 |
| P/OCF Ratio | 8.15 |
| PEG Ratio | 1.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.93, with an EV/FCF ratio of 11.77.
| EV / Earnings | 20.66 |
| EV / Sales | 2.75 |
| EV / EBITDA | 9.93 |
| EV / EBIT | 13.99 |
| EV / FCF | 11.77 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.75 |
| Quick Ratio | 1.04 |
| Debt / Equity | 1.34 |
| Debt / EBITDA | 3.36 |
| Debt / FCF | 3.98 |
| Interest Coverage | 5.32 |
Financial Efficiency
Return on equity (ROE) is 19.30% and return on invested capital (ROIC) is 11.27%.
| Return on Equity (ROE) | 19.30% |
| Return on Assets (ROA) | 6.45% |
| Return on Invested Capital (ROIC) | 11.27% |
| Return on Capital Employed (ROCE) | 13.27% |
| Weighted Average Cost of Capital (WACC) | 4.91% |
| Revenue Per Employee | $436,082 |
| Profits Per Employee | $58,034 |
| Employee Count | 3,023 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, Haemonetics has paid $51.73 million in taxes.
| Income Tax | 51.73M |
| Effective Tax Rate | 22.77% |
Stock Price Statistics
The stock price has increased by +0.20% in the last 52 weeks. The beta is 0.27, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +0.20% |
| 50-Day Moving Average | 76.18 |
| 200-Day Moving Average | 66.40 |
| Relative Strength Index (RSI) | 24.21 |
| Average Volume (20 Days) | 1,103,133 |
Short Selling Information
The latest short interest is 3.08 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 3.08M |
| Short Previous Month | 3.39M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 6.71% |
| Short Ratio (days to cover) | 4.60 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.32 billion and earned $175.44 million in profits. Earnings per share was $3.65.
| Revenue | 1.32B |
| Gross Profit | 793.78M |
| Operating Income | 259.00M |
| Pretax Income | 227.17M |
| Net Income | 175.44M |
| EBITDA | 364.90M |
| EBIT | 259.00M |
| Earnings Per Share (EPS) | $3.65 |
Balance Sheet
The company has $363.56 million in cash and $1.23 billion in debt, with a net cash position of -$861.45 million or -$18.54 per share.
| Cash & Cash Equivalents | 363.56M |
| Total Debt | 1.23B |
| Net Cash | -861.45M |
| Net Cash Per Share | -$18.54 |
| Equity (Book Value) | 911.45M |
| Book Value Per Share | 19.46 |
| Working Capital | 403.81M |
Cash Flow
In the last 12 months, operating cash flow was $338.84 million and capital expenditures -$30.76 million, giving a free cash flow of $308.08 million.
| Operating Cash Flow | 338.84M |
| Capital Expenditures | -30.76M |
| Free Cash Flow | 308.08M |
| FCF Per Share | $6.63 |
Margins
Gross margin is 60.21%, with operating and profit margins of 19.65% and 13.31%.
| Gross Margin | 60.21% |
| Operating Margin | 19.65% |
| Pretax Margin | 17.23% |
| Profit Margin | 13.31% |
| EBITDA Margin | 27.68% |
| EBIT Margin | 19.65% |
| FCF Margin | 23.37% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.04% |
| Shareholder Yield | 6.04% |
| Earnings Yield | 6.35% |
| FCF Yield | 11.15% |
Analyst Forecast
The average price target for Haemonetics is $86.00, which is 44.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $86.00 |
| Price Target Difference | 44.64% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.5 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.5 |
| Piotroski F-Score | 6 |